Advanced Soft-tissue Sarcoma Clinical Trial
Official title:
A Multicenter, Phase I/II Study Evaluating the Clinical Impact of HDM201 + Pazopanib in Patients With P53 Wild-type Advanced/ Metastatic Soft Tissue Sarcomas (AMPHISARC)
This trial is a two-step Phase I/II study comprising: Part 1: A dose escalation part with the aim to assess the safety of the proposed combination (N= up to 30 patients). In the dose escalation part, eligible patients will be treated with a fixed dose of pazopanib and escalating doses of HDM201. Part 2: An extension part to collect preliminary data about the clinical activity of the proposed combination according to the 6M-PFR.
This trial is a two-step Phase I/II study comprising: Part 1: A dose escalation part with the aim to assess the safety of the proposed combination (N= up to 30 patients). The dose escalation will be conducted according to a sequential and adaptive Bayesian scheme using the method of Time-to-event Continual Reassessment Method (CRM) to guide dose escalation and estimate the Maximum Tolerated Dose. In the dose escalation part, eligible patients will be treated with a fixed dose of pazopanib (800 mg/d) and escalating doses of HDM201: 60 mg (starting dose); 80 mg; 100 mg; 120 mg. For a safety reason, a dose level of 40 mg is included in case that the first dose level is found to be toxic. In addition, decrease of pazopanib dosing to 600 mg/d could be appropriate following protocol amendment. To ensure adequate patient safety during the dose escalation part, there will be a 3-day delay between the first and subsequent patients enrolled in each DL cohort to maximize the safety of enrolled patients. No intra-patient dose escalation is allowed. Part 2: An extension part to collect preliminary data about the clinical activity of the proposed combination according to the 6 months Progression Free Rate (6M-PFR). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05043649 -
Camsirubicin + Pegfilgrastim to Determine MTD in ASTS
|
Phase 1 | |
| Recruiting |
NCT05146440 -
Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination With Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05620693 -
Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma
|
N/A | |
| Recruiting |
NCT05809830 -
Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06367075 -
A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma
|
Phase 2 | |
| Recruiting |
NCT04874311 -
Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma
|
Phase 2 | |
| Recruiting |
NCT05876715 -
LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04757337 -
Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients
|
Phase 3 | |
| Recruiting |
NCT04705818 -
Combining Epigenetic And Immune Therapy to Beat Cancer.
|
Phase 2 | |
| Terminated |
NCT05154630 -
Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05099666 -
Lurbinectedin + Doxorubicin In Leiomyosarcoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03022448 -
Geriatric Assessmen of Elderly "Unsuited" Patients Receiving Trabectedin in First Line Treatment For Advanced Soft Tissue Sarcomas (STS)
|
||
| Recruiting |
NCT04204941 -
Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
|
Phase 3 | |
| Recruiting |
NCT05182164 -
Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
|
Phase 2 | |
| Terminated |
NCT04780464 -
A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma
|
Phase 3 |